XEN-D0501

DRUG4 trials

Sponsors

Pila Pharma AB, Xention Ltd, Pila Pharma

Conditions

Chronic Idiopathic CoughChronic Obstructive Pulmonary DiseaseDiabetes Mellitus, Type 2EfficacyObesityPharmacokineticsSafety

Phase 1

A two-part, randomised, double-blind, placebo-controlled, parallel-group, 12week trial investigating the safety, tolerability, pharmacokinetics and efficacy of XEN-D0501 in obese participants

Not yet recruitingCTIS2026-525869-42-00

Pila Pharma ABObesity

Target: 46Updated: 2026-08-13

Phase 2

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD

CompletedNCT02233686

Xention LtdChronic Obstructive Pulmonary Disease

Start: 2014-02-28End: 2015-02-28Updated: 2015-07-15

A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough

CompletedNCT02233699

Xention LtdChronic Idiopathic Cough

Start: 2014-07-31End: 2015-05-31Updated: 2015-07-15

A Trial Investigating the Effect of 4 Weeks Dosing of XEN-D0501 on Blood Glucose Reduction in Patients With Diabetes

CompletedNCT05353686

Pila PharmaDiabetes Mellitus, Type 2, Efficacy, Pharmacokinetics +1

Start: 2019-02-25End: 2019-12-19Updated: 2022-04-29